WVP
ACER

Worth Venture Partners’s Acer Therapeutics Inc ACER Stock Holding History

Worth Venture Partners’s Portfolio ACER Stock Details ACER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-250,518
Closed -$656K – 141
2020
Q4 		$656K Hold
250,518
– – 0.52% 53
2020
Q3 		$722K Buy
250,518
+91,731
+58% +$296K 0.59% 41
2020
Q2 		$544K Buy
+158,787
New +$448K 0.27% 62

Other funds holding ACER

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Worth Venture Partners's ACER Position: Q1 2021 in Review

Worth Venture Partners sold out of Acer Therapeutics Inc (ACER) in Q1 2021, closing a stake of 250,518 shares — an estimated $656K sold.

Worth Venture Partners first reported a position in ACER in Q2 2020 and held it in 3 quarters. The position peaked at $722K in Q3 2020. 30 funds tracked by Wall St. Rank hold ACER as of Q1 2021.

  • Worth Venture Partners reported no remaining Acer Therapeutics Inc position as of Q1 2021 after selling out during the quarter.
  • Worth Venture Partners sold 250,518 Acer Therapeutics Inc shares in Q1 2021, an estimated $656K.
  • Worth Venture Partners first reported a position in Acer Therapeutics Inc in Q2 2020 and held it in 3 quarters.
  • Worth Venture Partners's Acer Therapeutics Inc position peaked at $722K in Q3 2020.
  • 30 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q1 2021.

Based on Worth Venture Partners's 13F filing for Q1 2021, filed 17 May 2021.